Scroll Down Arrow

GCP for Clinical Trials with Investigational Drugs and Biologics (ICH Focus)

This course is suitable for individuals proposing to conduct clinical trials of drugs and biologics in the U.S. and internationally and/or who would prefer a more ICH-centric curriculum.


About this Course


The GCP ICH Basic course covers International Council for Harmonisation (ICH) E6 Good Clinical Practice (GCP) guideline essential topics for clinical trials with drugs and biologics. It describes the responsibilities and expectations for the conduct, monitoring, reporting, and documenting of clinical trials.

It is intended for research personnel involved in drug and biologic studies and who would benefit from a more internationally focused training, or for researchers involved in studies where compliance with ICH is required (for example, most industry-funded studies). It should be noted, however, that when appropriate, references to U.S. Food and Drug Administration (FDA) regulations and guidance are included.

The course covers key topics in clinical research including:

  • Reviewing ICH GCP standards
  • Reviewing FDA regulations
  • Identifying investigator and sponsor obligations
  • Discussing new drug development
  • Comparing ICH GCP E6 guideline and FDA regulations
  • Describing how to detect and report adverse events
  • Auditing and monitoring expectations

This course (English, Spanish, and Portuguese only) meets the Minimum Criteria for ICH GCP Investigator Site Personnel Training identified by TransCelerate BioPharma as necessary to enable mutual recognition of GCP training among trial sponsors. The course (all languages) is considered acceptable training by the National Institutes of Health (NIH) in fulfillment of their GCP training policy (Policy on Good Clinical Practice Training for NIH Awardees Involved in NIH-funded Clinical Trials; NOT-OD-16-148) that says NIH-funded investigators and staff should be trained in Good Clinical Practice (GCP).

Language Availability: English, Korean, Portuguese, Spanish

Suggested Audiences: IRB Members, Research Staff who are Involved in the Design, Conduct, Oversight, or Management of Clinical Trials with Drugs and/or Biologics, Clinical Research Coordinators, Clinical Research Organizations (CROs), Investigators, Key Study Personnel, Research Nurses, Sponsors

Organizational Subscription Price: Included in organizational subscription
Independent Learner Price: $110 per person


CE Credits and Units


To purchase CE credits and units, you need to be affiliated with an organization that subscribes to this course or buy it as an independent learner first.

Physicians

AMA PRA Category 1 Credit

4 Credits
(8 CE certified modules)
$70

17 October 2015
16 October 2018

Psychologists

CE Credit/Hour

4 Credits
(8 CE certified modules)
$70

17 October 2015
16 October 2018

Nurses

Contact Hour

4 Credits
(8 CE certified modules)
$60

3 July 2017
30 June 2019

Other Participants

Certificate of Participation

4 Credits
(8 CE certified modules)
$60

17 October 2015
16 October 2018


Course Content


Toggle Content The CITI Good Clinical Practice Course for Clinical Trials Involving Drugs and Biologics

Provides an introduction to the course and a link to the Belmont Report. The Belmont Report is required reading for all CITI Program participants as it provides the ethical framework for the federal regulations designed to protect human research subjects.

Recommended Use: Required
ID (Language): 14613 (English), 15273 (Spanish), 16359 (Portuguese), 16052 (Korean)

Toggle Content Overview of New Drug Development CME/CEU Badge

Describes the role of industry sponsors in the conduct of clinical trials under an investigational new drug (IND) application according to FDA regulations. Provides an overview of definitions, procedures, and timelines associated with the development of a new drug. Also covers electronic records and signatures pursuant to 21 CFR Part 11 and ClinicalTrials.gov requirements pursuant to 42 CFR Part 11.

Recommended Use: Required
ID (Language): 14621 (English), 15280 (Spanish), 16059 (Korean), 16336 (Portuguese)

Toggle Content Overview of ICH GCP CME/CEU Badge

Explains the role, purpose, and basic requirements of ICH E6 GCP guidelines and the impact on conducting clinical research according to GCP. Discusses when ICH GCP guidelines apply, provides an overview of the ICH topics and guidelines, reviews ICH E6 guideline, and discusses how these differ from the FDA regulations.

Recommended Use: Required
ID (Language): 14622 (English), 15281 (Spanish), 16366 (Portuguese), 16060 (Korean)

Toggle Content ICH - Comparison Between ICH GCP E6 and U.S. FDA Regulations CME/CEU Badge

Defines the role of ICH in the U.S. Expands on the discussion presented in ICH Overview comparing ICH GCP E6 guidelines and U.S. FDA regulations 21 CFR Parts 50 and 56. Presents the major differences between ICH guidelines and FDA regulations, including critical areas such as confidentiality of medical records, signature of the person conducting the consent discussion, and impartial witnesses for illiterate subjects. Also covers the differences between ICH GCP E6 and the FDA in terms of emergency situations, non-therapeutic trials, and investigator notification to subject’s primary physician, and IRB responsibilities.

Recommended Use: Required
ID (Language): 14625 (English), 15282 (Spanish), 16369 (Portuguese), 16061 (Korean)
Author(s): David G. Forster, JD, MA, CIP - Western IRB; Gary L. Chadwick, PharmD, MPH, CIP - University of Rochester / HRP Consulting Group, Inc.

Toggle Content Conducting Investigator-Initiated Studies According to FDA Regulations and GCP CME/CEU Badge

Discusses topics important to researchers who are also the sponsors of studies (sponsor-investigators) and conducting investigator-initiated studies. Covers how to determine whether an investigational new drug (IND) application is required, the role of the sponsor-investigator, documentation required for INDs, and reports that must be submitted to the FDA for active INDs. Also includes information on the additional responsibilities that sponsor-investigators assume in their dual role.

Recommended Use: Required
ID (Language): 14614 (English), 15274 (Spanish), 16360 (Portuguese), 16053 (Korean)

Toggle Content Investigator Obligations in FDA-Regulated Research CME/CEU Badge

Describes the commitments and obligations assumed by investigators when they conduct industry-sponsored clinical investigations under ICH E6 and investigational new drug (IND) requirements, including the requirements of the Form FDA 1572. Discusses investigator responsibilities including conduct of the study, reporting requirements, required study records, and communicating with the IRB, federal agencies, and sponsor.

Recommended Use: Required
ID (Language): 14615 (English), 15275 (Spanish), 16361 (Portuguese), 16054 (Korean)

Toggle Content Managing Investigational Agents According to GCP Requirements CME/CEU Badge

Describes the responsibilities of investigators when using investigational products according to GCP standards. This includes requirements for shipping and storage of investigational agents, as well as recording the receipt, use, and final disposition of investigational agents. Also reviews what constitutes investigational products and the management requirements for their use by study subjects.

Recommended Use: Required
ID (Language): 14617 (English), 15276 (Spanish), 16362 (Portuguese), 16055 (Korean)

Toggle Content Informed Consent in Clinical Trials of Drugs and Biologics CME/CEU Badge

Discusses informed consent requirements as reflected in both FDA regulations and ICH guidelines, including obtaining and documenting consent. Includes a discussion of the documentation of consent with specific discussion on the role of legally authorized representatives. Covers challenges associated with informed consent and the concept of vulnerable subjects, including issues related to subjects who cannot consent and the exceptions to the informed consent requirements.

Recommended Use: Required
ID (Language): 14618 (English), 15277 (Spanish), 16363 (Portuguese), 16056 (Korean)
Author(s): Diane Paul, MS, RN - Drug Development Associates, LLC

Toggle Content Monitoring Clinical Trials of Drugs by Industry Sponsors CME/CEU Badge

Describes the obligation of industry sponsors to monitor the progress of clinical trials under an investigational new drug (IND) application as well as the requirements for site record-keeping in studies that are regulated by the FDA and in adherence to ICH E6. Identifies the types of site visits conducted by sponsors, the basic requirements for each type of site visit, and the role of the investigative site during interactions with industry sponsors. Covers record keeping in studies regulated by the FDA and adhering to ICH E6 guideline.

Recommended Use: Required
ID (Language): 14619 (English), 15278 (Spanish), 16364 (Portuguese), 16057 (Korean)

Toggle Content Audits and Inspections of Clinical Trials of Drugs and Biologics CME/CEU Badge

Provides basic information on monitoring, audits, and inspections of clinical trials conducted according to ICH E6 standards for GCP. Describes the different entities that can inspect or audit a clinical trial, the factors that can determine whether an investigator will be audited, what the auditors and inspectors are looking for, and the results and consequences that can occur as a result of FDA inspection findings. Regulatory documents reviewed during inspections are presented and referenced to FDA and ICH GCP requirements. Some FDA-regulated research may also involve federal funding, thereby requiring oversight by the Office for Human Research Protections (OHRP). As a result, it includes information on OHRP compliance site visits and outcomes. The purpose of the FDA Bioresearch Monitoring Program is also discussed.

Recommended Use: Required
ID (Language): 14620 (English), 15279 (Spanish), 16365 (Portuguese), 16058 (Korean)

Toggle Content Detecting and Evaluating Adverse Events CME/CEU Badge

Defines adverse events (AEs) and related clinical trial terminology in accordance with ICH guidelines. Describes the process for identifying AEs in clinical research and identifies the factors to consider in assessing the severity and causality of AEs. Examples are provided to illustrate the evaluation process. Includes discussion on determining AE severity and causality, and the reporting of AEs to IRBs.

Recommended Use: Required
ID (Language): 14623 (English), 15283 (Spanish), 16367 (Portuguese), 16062 (Korean)

Toggle Content Reporting Serious Adverse Events in Investigations of Drugs and Biologics CME/CEU Badge

Identifies the criteria for investigators reporting serious adverse events (SAEs) to regulatory agencies and sponsors. Defines adverse events (AEs) and suspected adverse reactions and explains how AEs are classified as “life-threatening,” “serious,” or “unexpected” events. Reviews sponsor monitoring and reporting requirements of AEs. Discusses reporting safety information for bioavailability (BA) and bioequivalence (BE) studies, clinical trials involving marketed drugs, and blinded studies.

Recommended Use: Required
ID (Language): 14624 (English), 15284 (Spanish), 16368 (Portuguese), 16063 (Korean)

Toggle Content Completing the CITI GCP Course

Provides learners with instructions on how to review completed modules, download or print their completion report, or complete a form to order CME or CEU credits. Also provides links to U.S. federal regulations and other resources including Council for International Organizations of Medical Sciences (CIOMS), International Council for Harmonisation (ICH) Good Clinical Practices (E6), MedWatch (Safety Information and Adverse Event Reporting), and National Institutes of Health (NIH).

Recommended Use: Required
ID (Language): 14626 (English), 15285 (Spanish), 16370 (Portuguese), 16064 (Korean)


Additional Modules of Interest


Toggle Content Phase I Research: Understanding Phase I Research

Defines phase I research as it relates to non-clinical and other phases of research. Identifies routine study designs used to develop the initial safety profile and achieve study objectives in phase I research. Reviews the importance of phase I research on drug development.

Recommended Use: Supplemental
ID (Language): 16873 (English)
Author(s): Julie Blasingim, BA, MBA, CIP - Schulman Associates IRB

Toggle Content Phase I Research: Protecting Phase I Subjects

Reviews U.S. Food and Drug Administration (FDA) requirements for initiation of phase I research studies following non-clinical studies. Describes IRB considerations for review of phase I research. Identifies ways in which researchers and staff involved in phase I research can apply the necessary safeguards to protect subjects including selecting a safe starting does, safeguards for standard dosing regimens, selecting appropriate subjects, facility safeguards, and the role of informed consent.

Recommended Use: Supplemental
ID (Language): 16874 (English)
Author(s): Julie Blasingim, BA, MBA, CIP - Schulman Associates IRB

Toggle Content Overview of the Clinical Trial Agreement (CTA)

Discusses the general purpose of a CTA, roles and responsibilities of parties to the CTA, and how the CTA fits into the research enterprise. It also compares and contrasts clinical trials involving drugs, biologics, and devices from a CTA perspective.

Recommended Use: Supplemental
ID (Language): 17356 (English)
Author(s): Dex Bilkic, HBSc, MBA - Boehringer-Ingelheim; JoAnn Pfeiffer, DrSC, RAC, CCRA - Arizona State University

Toggle Content Understanding the Terms of the Clinical Trial Agreement (CTA)

Provides an overview of the context behind certain CTA terms and sections, types of language used for CTA sections, and some key elements of each section. It also outlines what should be addressed in the key sections of the CTA and the aim for each section.

Recommended Use: Supplemental
ID (Language): 17357 (English)
Author(s): Dex Bilkic, HBSc, MBA - Boehringer-Ingelheim; JoAnn Pfeiffer, DrSC, RAC, CCRA - Arizona State University

Toggle Content Role of the Researcher and Site in Managing the Clinical Trial Agreement (CTA)

Discusses key roles of the researcher and site in managing the CTA, including initial assessment, review, and implementation. It also describes how the CTA is linked to site policies, the protocol, and the informed consent form, and identifies key sections of the CTA that could present risk to the site.

Recommended Use: Supplemental
ID (Language): 17358 (English)
Author(s): Dex Bilkic, HBSc, MBA - Boehringer-Ingelheim; JoAnn Pfeiffer, DrSC, RAC, CCRA - Arizona State University

Toggle Content Clinical Trial Agreement (CTA) Negotiation for Researchers and Sites

Addresses strategies and preparation for CTA and study budget negotiations. It also identifies terminology and alternative wording options to ensure a fair and balanced CTA.

Recommended Use: Supplemental
ID (Language): 17359 (English)
Author(s): Dex Bilkic, HBSc, MBA - Boehringer-Ingelheim; JoAnn Pfeiffer, DrSC, RAC, CCRA - Arizona State University